MedTrace Logo

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2010-09-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.

Conditions

Interventions

DRUG

Budesonide/formoterol (SYMBICORT) pMDI

DRUG

Formoterol Turbuhaler

Sponsors & Collaborators

Principal Investigators

  • Christer Hultquist, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States
  • Argentina
  • Brazil
  • Chile
  • Colombia
  • Mexico
  • Peru
  • South Africa
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419744 on ClinicalTrials.gov